Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nuclein LLC is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are being handled by 2 distinct examiners, which indicates that no single official is responsible for more than one case. This arrangement requires the applicant to adapt to the specific preferences and legal interpretations of two different individuals. The absence of examiner concentration suggests that the prosecution of these 2 pending office actions will proceed along independent tracks.
The company's active cases are distributed across 2 distinct art units, highlighting the technical variety within their biotechnological filings. This spread across multiple art units means that the 2 pending office actions may be subject to different internal guidelines and examination speeds. CROW, ROBERT THOMAS is identified as the busiest examiner for the portfolio, currently managing 1 pending office action. Since this busiest examiner is responsible for 1 of the 2 pending actions, the workload is not concentrated in any single office.
For those managing the Nuclein LLC portfolio, the use of 2 distinct examiners across 2 distinct art units necessitates a careful review of all correspondence to ensure technical consistency. The fact that CROW, ROBERT THOMAS holds 1 pending action means that the other action is being reviewed by a separate official. This distribution provides a diversified exposure to the patent office's examination corps for the 2 pending office actions currently in progress.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CROW, ROBERT THOMAS | 1 | 41.6% | +32.5% |
| KRCHA, MATTHEW D | 1 | 64.3% | +35.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558061 | ANALYTE DETECTION CARTRIDGE AND METHODS OF USE THEREOF | CROW, ROBERT THOMAS | — |
| 18037282 | APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | KRCHA, MATTHEW D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558061 | ANALYTE DETECTION CARTRIDGE AND METHODS OF USE THEREOF | CROW, ROBERT THOMAS | — |
| 18037282 | APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | KRCHA, MATTHEW D | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558061 | ANALYTE DETECTION CARTRIDGE AND METHODS OF USE THEREOF | CROW, ROBERT THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18037282 | APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS | KRCHA, MATTHEW D | 1796 | §103§112 | Final Rejection | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuclein LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert Thomas Crow has the most, with 1 of Nuclein LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
